IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)

Is This Study For You?

Let's Get Started!


Study IMVT-1401-3201 is a Phase 3, multi-center, randomized, quadruple‑masked (Sponsor, Investigator, assessor, and participant), placebo‑controlled study was designed to assess the efficacy and safety of batoclimab in adult participants with active, moderate to severe TED. The study duration for an individual participant may be up to 32 weeks.




The study population will consist of participants 18 years or older who have active, moderate to severe TED.


University of Colorado Hospital

Principal Investigator
Photograph of Prem Subramanian

Prem Subramanian

Study ID

Protocol Number: 22-1591

More information available at NCT05517421


Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers